FDA Perspectives: Designation of Regulatory Starting Materials in the Manufacturing of Drug Substances: Impact on ANDA Review Time - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

FDA Perspectives: Designation of Regulatory Starting Materials in the Manufacturing of Drug Substances: Impact on ANDA Review Time
The author describes how providing appropriate information about the API in the Common Technical Document can aid FDA's review of an abbreviated new drug application.


Pharmaceutical Technology
Volume 36, Issue 1, pp. 63-66

References

1. R. Giralt, "A New Definition for API Starting Materials," Pharmaceutical Technology Europe 16 (6), 2004.

2. ICH, Q11: Development and Manufacture of Drug Substances (ICH, May 2011).

3. ICH Q9, Quality Risk Management (ICH, June 2006). This is directly applicable to the drug product manufacture but also applies the risk-based thinking with regard to the drug substance.

4. Muller et al., "A Rationale for Determining, Testing, and Controlling Specific Impurities in Pharmaceuticals that Possess Potential for Genotoxicity," Regulatory Toxicology and Pharmacology 44, 198–211, (2006).

5. A. Thayer, "Genotoxic Impurities," C&E News Sept. 2010, 88 (39), pp. 16–26.

6. FDA, Draft Guidance for Industry: Fermentation Derived Intermediates, Drug Substances, and Related Drug Products (FDA, Dec. 2002)

7. S. Schaeffer, "Equivalence Test Case," Biocentury 18 (34), A1–A7 (2010).

8. ICH, Q8(R2) "Quality Target Product Profile" definition; see also Spring 2011 GPHA Meeting Slides by R. Lionberger; Yu, Pharm. Res. 25 781–791, 2008.

Disclaimer

The views and opinions in this article are only those of the author and do not necessarily reflect the views or policies of the US Food and Drug Administration.

Acknowledgments

The author thanks Naiqi Ya, Dave Skanchy, Bob Iser, and Aloka Srinivasan for their scientific input.

Barbara Scott is a chemistry and manufacturing reviewer (CMC) at the Office of Generic Drugs within the Office of Pharmaceutical Science, under the US Food and Drug Administration's Center for Drug Evaluation and Research,
.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
25%
Oversee medical treatment of patients in the US.
13%
Provide treatment for patients globally.
10%
All of the above.
43%
No government involvement in patient treatment or drug development.
10%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here